Net loss for Q1 2026 increased to $40.2 million, up 139% from $16.8 million in Q1 2025. Product revenue, net, grew to $6.9 million in Q1 2026 from $2.4 million in Q1 2025, primarily due to the commercial launch of TONMYA. Research and development expenses surged by 146% to $18.2 million in Q1 2026, up from $7.4 million in Q1 2025. Selling, general and administrative expenses increased by 183% to $28.6 million in Q1 2026, compared to $10.1 million in Q1 2025, largely due to TONMYA's launch. Cash and cash equivalents decreased to $185.5 million as of March 31, 2026, from $207.6 million at December 31, 2025. The company issued a going concern warning, stating current cash resources, even with recent equity raises, will not cover operating and capital expenditure requirements for the next 12 months from the filing date. Weighted average common shares outstanding significantly increased to 13,707,104 in Q1 2026 from 5,927,231 in Q1 2025, indicating substantial dilution.